NA
FDMT icon

NewEdge Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

NewEdge Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.97K Hold
212
– – ﹤0.01% 3815
2025
Q4 		$1.59K Hold
212
– – ﹤0.01% 3922
2025
Q3 		$1.84K Buy
+212
New +$1.27K ﹤0.01% 3790

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NewEdge Advisors's FDMT Position: Q1 2026 in Review

NewEdge Advisors held its 4D Molecular Therapeutics (FDMT) position steady in Q1 2026 at 212 shares worth $1.97K. The position accounts for ﹤0.01% of the portfolio, ranked #3815.

NewEdge Advisors first reported a position in FDMT in Q3 2025 and has held it in 3 quarters since. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • NewEdge Advisors held 212 shares of 4D Molecular Therapeutics worth $1.97K as of Q1 2026.
  • NewEdge Advisors left its 4D Molecular Therapeutics share count unchanged in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3815 holding.
  • NewEdge Advisors first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.